(Carregando Índice)...

Reproduzido de:

Formulário Terapêutico Nacional 2008: Rename 2006 [Link Livre para o Documento Original]

Série B. Textos Básicos de Saúde

MINISTÉRIO DA SAÚDE

Secretaria de Ciência, Tecnologia e Insumos Estratégicos

Departamento de Assistência Farmacêutica e Insumos Estratégicos

Brasília / DF – 2008

 

REFERÊNCIAS

 

1.        World Health Organization. WHO model formulary 2006. Geneva: WHO; 2006. Available from: <http://mednet3.who.int/EMLib/modelFormulary/modelFormulary. asp>.

2.        British Medical Association, the Royal Pharmaceutical Society of Great Britain. British National Formulary. 54th. ed. London: BMJ Publishing Group and RPS Publishing; 2007.

3.        British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group. British National Formulary for Children. London: BMJ Publishing Group, RPS Publishing and RCPCH Publications; 2007.

4.        Klasco RK, editor. USP DI Drug Information for Health Care Professional [Database on the Internet]. Greenwood Village (Colorado): Thomson MICROMEDEX; 1974-2006. [Cited 2006 Oct 5]. Available from: <http://www.periodicos.capes.gov.br>.

5.        Klasco RK, editor. DRUGDEX System [Database on the Internet]. Greenwood Village (Colorado): Thomson MICROMEDEX; 1974-2006. [Cited 2006 Oct 5]. Available form: <http://www.periodicos.capes.gov.br>.

6.        Klasco RK, editor. Martindale: the extra pharmacopoeia. [Database on the Internet]. Greenwood Village (Colorado): Thomson MICROMEDEX; 1974-2006. [Cited 2006 Oct 5]. Available from: <http://www.periodicos.capes.gov.br>.

7.        Escola Nacional de Saúde Pública. Núcleo de Assistência Farmacêutica. Fundamentos farmacológicos-clínicos dos medicamentos de uso corrente 2002. Rio de Janeiro: ENSP; 2002. [CD-rom]

8.        Wannmacher L, Bermudez JAZ, Reis, ALA, Osorio-de-Castro CGS, Pepe VLE, Luiza VL, Bonfim J R.A, Silver LD, Marín N. Formulário Terapêutico Nacional. Rio de Janeiro : ENSP; 2000. [mimeo]

9.        Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook 2005-2006. Hudson: Lexi-Comp; 2005.

10.     Tatro DS, editor. Drug Interaction Facts 2005: the authority on drug interactions. St. Louis: Facts & Comparisons; 2005.

11.     Briggs GG, Freeman RK, Yafee SJ. Drugs in pregnancy and lactation. 6th. ed. Philadelphia: Williams & Wilkins; 2005.

12.     Dukes MNG, Aronson JK, editors. Meyler’s side effects of drugs. 14th. ed. Amsterdam: Elsevier; 2000.

13.     McEvoy GK, editor. AHFS Drug information. Bethesda, MD: ASHP; 2006.

14.     Kliemann FAD, Monte TL. Antiepilépticos. In: Fuchs, FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004: 536-53.

15.     Pohlmann-Eden B, Beghi E, Camfield C, Camfield P. The first seizure and its management in adults and children. BMJ 2006; 332:339-42.

16.     Sills GJ. Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res 2003, 53: 2-6.

17.     Deckers CL, Hecster YA, Keyser A, van Lier HJ, Meinardi H, Renier WO. Monotherapy versus politherapy for epilepsy: a multicenter double blind randomized srudy. Epilepsia 2001; 42:1387-94.

18.     Leppik IE. Monotherapy and polypharmacy. Neurology 2000; 55(Supl 3): S25-S29.

19.     Deckers CL. Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res 2003; 53: 10-14.

20.     BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain. British National Formulary. 50th. ed. London: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain; September 2005: 239.

21.     Shorvon S. A handbook of epilepsy treatment. Oxford: Blackwell Science; 2000: 248.

22.     WHO Expert Committee on the Selection and Use of Essential Medicines. The Selection and Use of Essential Medicines: report of the WHO Expert Committee, 2005: 11 [WHO Technical Report Series; 933]

23.     Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000; 356:323-9.

24.     Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58 (Suppl 5): S2-S8.

25.     Avoli M, Rogawaski MA, Avanzini G. Generalized epileptic disorders: an update. Epilepsia 2001; 42:445-57.

26.     Shorvon S. The management of status epilepticus. J Neurol Neurosurg Psychiatr 2001; 70 (Suppl II): II22-II27.

27.     Walker M. Status epilepticus: an evidence based guide. BMJ 2005; 331: 673-77.

28.     Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345: 631-7.

29.     Chamberlain JM, Altieri MA, Futterman C, Young GM, Ochsenschlager DW, Waisman Y. A prospective, randomized study comparing intramuscular Midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care 1997; 13:92-4.

30.     BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain. British National Formulary. 50th. ed. London: BMJ Publishing Group, Royal Pharmaceutical Society of Great Britain; September 2005:243.

31.     Treiman DM. Treatment of convulsive status epilepticus. Int Rev Neurobiol 2007; 81:273-85.

32.     Report OMS WHO Expert Committee on the Selection and Use of Essential Medicines. The Selection and Use of Essential Medicines: report of the WHO Expert Committee, 2007 [Unedited prepublication] Available from: <http://www.who.int/medicines/areas/rational_use/en/index.html>.

33.     The Eclâmpsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the collaborative eclampsia trial. Lancet 1995; 345:1455-63.

34.     Wannmacher L. Manejo da hipertensão na gravidez: o pouco que se sabe. In: OPAS. Uso racional de medicamentos Temas Selecionados. Brasília, DF; 2004. [OPAS, volume 1, número 11].

35.     Duley L, Gülmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other anticonvulsants for women with pre-eclâmpsia (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software.

36.     Magpie Trial Collaboration Group. Do women with pre-eclâmpsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebocontrolled trial. Lancet 2002; 359:1877-90.

37.     Duley L, Henderson-Smart D. Magnesium sulphate versus phenytoin for eclampsia (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software.

38.     Duley L, Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software.

39.     Posner E. Absence seizures in children. BMJ Clinical Evidence [online] 2007 Feb [cited 2007 May 25]. Available from: <http://clinicalevidence.bmj.com/ceweb/conditions/chd/0317/0317_I1.jsp>.

40.     Geddes J, Briess D. Bipolar disorder: treatments for mania. BMJ Clinical Evidence [online] 2007 Feb [cited 2007 May 25]. Available from: <http://clinicalevidence.bmj.com/ceweb/conditions/meh/1014/1014_I2.jsp.>

41.     Marson A, Ramaratnam S. Epilepsy. BMJ Clinical Evidence [online] 2007 Feb [cited 2007 May 25]. Available from: <http://clinicalevidence.bmj.com/ceweb/conditions/nud/1201/1201.jsp>.

42.     Hazell P. Depression in children. May go unnoticed and untreated. BMJ 2002; 325:229-30.

43.     Hazell P, O’Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software.

44.     Hazell P. Depression in adolescents. BMJ 2007; 335:106-7. [Editorial]

45.     Goodyer I, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomized controlled trial. BMJ 2007 335: 142.

46.     Howard LM, Hoffbrand S, Henshaw C, Boath L, Bradley E. Antidepressant prevention of postnatal depression (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software.

47.     Hoffbrand S, Howard L, Crawley H. Antidepressant treatment for post-natal depression (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software.

48.     Antidépresseurs IRS et malformations congénitales. Rev Prescr 2006; 26 (273):430-1.

49.     Mynors-Wallis LM, Gath DH, Day A, Baker F. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. BMJ 2000; 320:26-30.

50.     Wannmacher L. Fármacos usados nos distúrbios afetivos. In: Fuchs, FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004: 587-604.

51.     Wannmacher L. Depressão maior: da descoberta à solução. In: OPAS. Uso racional de medicamentos Temas Selecionados. Brasília; 2004. [OPAS, volume 1, número 5].

52.     Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 2005; 3 (5):449-56.

53.     MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003; 326 (7397): 1014.

54.     Barbui C, Butler R, Cipriani A, Geddes J, Hatcher S. Depression in adults (drug and other physical treatments). BMJ Clinical Evidence. [Web publication date: 01 Jun 2007 (based on April 2006 search)]

55.     Keck PE Jr, McElroy SL. Redefining mood stabilization. J Affect Disord 2003; 73:163-9.

56.     Guaiana G, Barbui C, Hotopf M. Amitriptyline versus other types of pharmacotherapy for depression (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software.

57.     Stage KB; Danish University Antidepressant Group. Orthostatic side effects of clomipramine and moclobemide during treatment for depression. Nord J Psychiatr 2005; 59(4): 298-301.

58.     Dusseldorp E, Spinhoven P, Bakker A, van Dyck R, van Balkom AJ. Which panic disorder patients benefit from which treatment: cognitive therapy or antidepressants? Psychother Psychosom 2007; 76 (3): 154-61.

59.     Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR. Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry 2006; 67 (2):269-76.

60.     Reynolds III CF, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, et al. Nortriptyline and Interpersonal Psychotherapy as Maintenance Therapies for Recurrent Major Depression. A Randomized Controlled Trial in Patients Older Than 59 Years. JAMA 1999;281:39-45.

61.     Wisner KL, Hanusa BH, Perel JM, Peindl KS, Piontek CM, Sit DK, Findling RL, Moses-Kolko EL. Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol 2006 ; 26 (4):353-60.

62.     Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 2007; 130 (1-2):66-75.

63.     Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M, Malvini L, Barbui C. Fluoxetine versus other types of pharmacotherapy for depression (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software.

64.     McKenzie MS, McFarland BH. Trends in antidepressant overdoses. Pharmacoepidemiol Drug Saf 2007; 16 (5):513-23.

65.     Maj M. The effect of lithium in bipolar disorder: a review of recent research evidence. Bipolar Disord 2003; 5: 180-8.

66.     Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G. Lithium for maintenance treatment of mood disorders (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software.

67.     Geddes J, Briess D. Bipolar Disorder. BMJ Clinical Evidence. [Web publication date: 01 May 2006 (based on November 2004 search)]

68.     Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of longterm treatments. Acta Psychiatr Scand 2003; 108:4-14.

69.     Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA; LitCar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatr 2003; 64:144-51.

70.     Macritchie K, Geddes JR, Scott J, Haslam D, Lima M, Goodwin G. Valproate for acute mood episodes in bipolar disorder (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software

71.     Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproato and divalproex in the maintenance treatment of bipolar disorder (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software.

72.     Rieder CRM, Rotta FT. Antiparkinsonianos. In: Fuchs, FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004: 554-63.

73.     British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 53th. ed. London: BMJ Publishing Group and APS Publishing; 2007. Available from: <http://www.bnf.org>.

74.     Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: Initiation of treatment for Parkinson‘s disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58:11-7.

75.     Koller WC. Treatment of early Parkinson’s disease. Neurology 2002; 58: S79-S86.

76.     Nadeem Z, McIntosh A, Lawrie S. Schizophrenia. BMJ Clinical Evidence. [Web publication date: 01 Nov 2006 (based on September 2005 search) ]

77.     Moreira LB, Costa AF, Fuchs FD. Antipsicóticos. In: Fuchs, FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004:577-86.

78.     Geddes J, Freemantle N, Harrison P, Bebeington P. Atypical antipsychotics in the treatment of schizophrenia: systematic review and meta-regression analysis. BMJ 2000; 321:1371-6.

79.     Wannmacher L Antipsicóticos atípicos: mais eficazes, mais seguros? In: OPAS. Uso racional de medicamentos: temas selecionados. Brasília, DF; 2004. [OPAS, v. 1, n. 12].

80.     Davis JM.The Choice of Drugs for Schizophrenia. N Engl J Med 2006; 354 (5): 518-20. [Editorial]

81.     Adams CE, Awad G, Rathbone J, Thornley B. Chlorpromazine versus placebo for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

82.     Almerie MQ, Alkhateeb H, Essali A, Matar HE, Rezk E. Cessation of medication for people with schizophrenia already stable on chlorpromazine (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

83.     Waraich PS, Adams CE, Roque M, Hamill KM, Marti J. Haloperidol dose for the acute phase of schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

84.     Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

85.     Quraishi S, David A. Depot haloperidol decanoate for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

86.     Guimarães FS. Hipnóticos e ansiolíticos. In: Fuchs, FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004: 564-76.

87.     Wannmacher L. Como manejar a insônia em idosos: riscos e benefícios. In: OPAS. Uso Racional de Medicamentos Temas Selecionados. Brasília; 2007. [OPAS, v. 4, n. 5].

88.     Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Assoc J 2000; 25: 225-33.

89.     Charney DS, Mihic SJ, Harris RA. Hypnotics and sedatives. In: Brunton LA, Lazo JS, Parker KL, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th. ed. New York: McGraw-Hill; 2006: 401-27.

90.     Dundar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess 2004; 8 (24):1-125.

91.     Carlson G, Roy-Byrne P. Treatment of generalized anxiety disorder: do benzodiazepines still have a role ? In: Nutt D, Rickels K, Stein D, eds. Generalized anxiety disorder. London: Martin Dunitz; 2002:111-23.

92.     Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002; 3: 171-99.

93.     Heyman I, Mataix-Cols D, Fineberg NA. Obsessive-compulsive disorder. BMJ 2006; 333:424-9.

94.     Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 2005; 8 (1):107-29.

95.     Wolkove N, Elkholy O, Baltzan M, Palayew M. Sleep and aging: 2. Management of sleep disorders in older people. CMAJ 2007; 176 (10):1449-54.

96.     Hsin YL, Chuang MF, Shyu WC, Lin CY, Chen YH, Harnod T. Adult-onset autosomal dominant myoclonic epilepsy: report of a family with an overlooked epileptic syndrome. Seizure 2007;16 (2):160-5.

97.     Glass GA, Ahlskog JE, Matsumoto JY. Orthostatic myoclonus: a contributor to gait decline in selected elderly. Neurology 2007; 68 (21): 1826-30.

98.     McKelvie R. Heart failure. In: BMJ Clinical Evidence. [Web publication date: 01 Jan 2007 (based on February 2006 search)]

99.     Gus M, Rohde LE, Fuchs FD. Fármacos usados em insuficiência cardíaca. In: Fuchs, FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004: 705-18.

100.  The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336:525-33.

101.  Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871-8.

102.  Hood WB, Dans AL, Guyatt GH, et al. Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 2004; 10:155–64.

103.  Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.

104.  Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-51.

105.  Fuchs FD. Diuretics: drugs of choice for the initial management of patients with hypertension. Exp Rev Cardiov Med 2003; 1: 35-41.

106.  Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. JAMA 1997; 277: 739-45.

107.  Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273:1450–6.

108.  The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Eng J Med 1987; 316:1429-35.

109.  The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Eng J Med 1991; 325: 669-77.

110.  The SOLVD investigators. Effect of enalapril on mortality and development of heart failure in assimptomatic patients with reduced left ventricular ejection fractions. N Eng J Med 1992; 327: 685-91.

111.  MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.

112.  Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362:7-13.

113.  Metra M, Torp-Pedersen C, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Dei Cas L, Spark P, Swedberg K, Poole-Wilson PA; for the COMET investigators. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail Jun 18, 2007.

114.  Remme WJ, Torp-Pedersen C, Cleland JG, Poole-Wilson PA, Metra M, Komajda M, Swedberg K, Di Lenarda A, Spark P, Scherhag A, Moullet C, Lukas MA. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol 2007; 49 (9):963-71.

115.  Dicionário de Administração de Medicamentos na Enfermagem 2005/2006. 4ª. ed. Rio de Janeiro: EPUB; 2004

116.  Page CP, Curtis MJ, Sutter MC, Walker MJA, Hoffman BB. Farmacologia integrada. São Paulo: Manole; 1999. 606p.

117.  UpToDate online [Internet] version 15.3. Furosemide. In: UpToDate, Rose BD (Editors), UpToDate, Waltham, MA, 2007. [cited 2007 Dec 8]. Available from: <http://www.utdol.com/utd/content/search.do?search=furosemide&searchOffset=0&source=MISSPELL>.

118.  Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004.

119.  UpToDate online [Internet] version 15.3. Hydrochlorothiazide.In: UpToDate, Rose BD, editors, UpToDate, Waltham, MA, 2007. [Cited 2007 Dec 8]. Available from: <http://www.utdol.com/utd/content/search.do?search=hydroclorothiazide&searchOffset=0&source=MISSPELL>.

120.  Hoffman B, Page C, Curtis M, Walker M, Sutter M. Farmacologia integrada. 2a. ed. São Paulo: Manole; 2004.

121.  UpToDate online [Internet] version 15.3. Metoprolol. In: UpToDate, Rose BD (Editors), UpToDate, Waltham, MA, 2007. [cited 2007 Dec 8]. Available from: <http://www.utdol.com/utd/content/search.do?search=metoprolol&searchOffset=0&source=MISSPELL>.

122.  Zimerman L, Fuchs FD. Antiarrítmicos. In: Fuchs, FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004:719-32.

123.  Echt DS, Liebson PR, Mitchell LB, et al. The Cardiac Arrhythmia Supression Trial (CAST): Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991; 324: 781-8.

124.  Crystal E, Garfinkle MS, Connolly SS, Ginger TT, Sleik K, Yusuf SS. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

125.  Zebis LR, Christensen TD, Thomsen HF, Mikkelsen MM, Folkersen L, Sorensen HT, Hjortdal VE. Practical regimen for amiodarone use in preventing postoperative atrial fibrillation. Ann Thorac Surg 2007; 83 (4):1326-31.

126.  Giri A, White M, Dunn AB, et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial: a randomized placebo-controlled trial. Lancet 2001; 357: 830-6.

127.  Gosselink ATM, Crijns HJ, Van Gelder IC, et al. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267: 3289-93.

128.  Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, Mahé I, Bergmann J-F. Antiarrhythmic Drugs for Maintaining Sinus Rhythm After Cardioversion of Atrial Fibrillation. A Systematic Review of Randomized Controlled Trials. Arch Intern Med 2006: 166 (7):719-28.

129.  Crijns HJGM, Van Gelder IC, Kingma JH, et al. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by class IC drug. Eur Heart J 1994; 15:1403-8.

130.  Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrythmias. J Am Coll Cardiol 1996; 27:67-75.

131.  Doval HC, Nul DR, Grancelli HO, et al. Randomized trial of low-dose amiodarone in severe heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. Lancet 1994;344:493-8.

132.  Amiodarone Trials Meta-analysis Investigators. Effect of prophylatic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: metaanalysis of individuals data from 6500 patients in randomized trials. Lancet 1997; 350:1417-24.

133.  Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Eng J Med 2002; 346: 884-90.

134.  Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999; 341:871-8.

135.  Suttorp MJ, Kingma JH, Tjon RM, et al. Efficacy and safety of low and high dose sotalol versus propranolol in the prevention of supraventricular tachyarrythmias early after coronary artery bypass surgery. J Thorac Cardiovasc Surg 1996; 100: 91-96.

136.  Miller JM, Zipes DP. Therapy for cardiac arrhythmias. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald´s Heart Disease. 7th. ed. Philadelphia: Elsevier Saunders; 2005: 713-66.

137.  Tsuneda T, Yamashita T, Fukunami M, Kumagai K, Niwano S, Okumura K, Inoue H. Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study. Circ J 2006; 70 (8): 965-70.

138.  Sticherling C, Behrens S, Kamke W, Stahn A, Zabel M. Comparison of acute and longterm effects of single-dose amiodarone and verapamil for the treatment of immediate recurrences of atrial fibrillation after transthoracic cardioversion. Europace 2005; 7(6):546-53.

139.  Vijayalakshmi K, Whittaker VJ, Kunadian B, Graham J, Wright RA, Hall JA, Sutton A, de Belder MA. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart 2006; 92 (9):1278-84.

140.  UpToDate online [Internet] version 15.3. Atenolol.In: UpToDate, Rose BD (Editors), UpToDate, Waltham, MA, 2007. [cited 2007 Dec 8]. Available from: <http://www.utdol.com/utd/content/search.do?search=atenolol&searchOffset=0&source=MISSPELL>.

141.  Cardoso SR, Martins C. Interação droga-nutriente [Drug-food interactions]. Curitiba: Nutro-Clínica; 1998.

142.  Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol 2005; 61:337-40.

143.  UpToDate online [Internet] version 15.3. Verapamil. In: UpToDate, Rose BD, editors, UpToDate, Waltham, MA, 2007. [cited 2007 Dec 8]. Available from: <http://www.utdol.com/utd/content/search.do?search=verapamil&searchOffset=0&source=MISSPELL>.

144.  Martins C, Moreira SM, Pierosan SR. Interações droga-nutriente. 2a. ed. Curitiba: NutroClínica; 2003.

145.  Polanczyk CA, Gus M, Fuchs FD. Fármacos usados em cardiopatia isquêmica. In: Fuchs, FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004:644-67.

146.  Juul-Möller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Doubleblind trial of aspirin in prevention of miocardial infarction in patients with chronic angina pectoris. Lancet 1992; 340:1421-4.

147.  Danchin N, Durand E. Acute myocardial infarction. In: BMJ Clinical Medicine. [Web publication date: 01 Mar 2006 (based on August 2004 search)]

148.  Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.

149.  Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-53.

150.  Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71–86.

151.  Abramson J, Wright JM. Are lipid-lowering guidelines evidence-based? Lancet 2007; 369: 168-9.

152.  The Scandinavian Survival Study Group. Randomized trial of cholesterol lowering in 4.444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.

153.  Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J; 4S Group. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364 (9436):771-7.

154.  Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292 (11):1307-16.

155.  Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363 (9411):757-67.

156.  O’Toole L. Angina (stable). BMJ Clinical Evidence. Web publication date: 01 Apr 2007 (based on December 2005 search)]

157.  Morrow DA, Gersh BJ, Braunwald E. Chronic coronary artery disease. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald´s Heart Disease. 7th. ed. Philadelphia: Elsevier Saunders; 2005:1281-354.

158.  Destors JM, Boissel JP, Philippon AM, et al. Controlled clinical trial of bepridil, propranolol and placebo in the treatment of exercise induced angina pectoris. Fundam Clin Pharmacol 1989; 3:597–611.

159.  Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris: the Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17:76–81.

160.  Singh S. Long-term double-blind evaluation of amlodipine and nadolol in patients with stable exertional angina pectoris. Clin Cardiol 1993; 16: 54–58.

161.  Hall R, Chong C. A double-blind parallel-group study of amlodipine versus longacting nitrate in the management of elderly patients with stable angina. Cardiology 2001; 96:72–77.

162.  Karlberg KE, Saldeen T, Wallin R, et al. Intravenous nitroglycerine reduces ischaemia in unstable angina pectoris: a double-blind placebo-controlled study. J Intern Med 1998; 243:25–31.

163.  Natarajan M. Angina (unstable). BMJ Clinical Evidence. [Web publication date: 01 Oct 2005 (based on March 2004 search)]

164.  Cannon CP, Braunwald E. Unstable angina and non-ST elevation myocardial infarction. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald´s Heart Disease. 7th. ed. Philadelphia: Elsevier Saunders; 2005:1243-79.

165.  Antman EM. ST-elevation myocardial infarction management. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald´s Heart Disease. 7th. ed. Philadelphia: Elsevier Saunders; 2005: 1167-226.

166.  Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomized, double-blind, placebo-controlled trial. Circulation 1986; 73:331–7.

167.  HINT Research Group. Early treatment of unstable angina in the coronary care unit: a randomized, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986; 56:400–13.

168.  MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J 1985; 6:199-226.

169.  ISIS-1 Group. Randomized trial of intravenous atenolol among 16.027 cases of suspected acute myocardial infarction. Lancet 1986; 2:57-65.

170.  Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:1730–7.

171.  Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) II-B study. Circulation 1991; 83: 422–37.

172.  Douchet S, Malekianpour M, Theroux P, et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary or restenosis after coronary artery angioplasty. Circulation 2000; 101:955–61.

173.  Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998; 21: 633–41.

174.  Wilcox RG, Hampton JR, Banks DC, et al. Early nifedipine in acute myocardial infarction: the TRENT study. BMJ 1986; 293:1204–8.

175.  Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction: the Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993; 153:345–53.

176.  Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33: 598–604.

177.  ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomised trials. Circulation 1998;97:2202–12.

178.  Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensina converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. Systematic overview of individual data from 96 712 randomized patients. J Am Coll Cardiol 2000; 35:1801–7.

179.  Théroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during acute phase of unstable angina. Circulation 1993; 88:2045-8.

180.  Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after discontinuation of heparin. N Engl J Med 1992; 327:141-5.

181.  The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO trial. N Engl J Med 1993; 329:673-80.

182.  Grupo Italiano per Lo Studio Della Sopravivenza Nell’infarto Miocardico. GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus on heparin among 12.490 patients with myocardial infarction. Lancet 1990; 336:65-71.

183.  Third International Study of Infarct Survival (ISIS-3) Collaborative Group. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339:753-70.

184.  The ASSENT-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358:605-13.

185.  Wallentin L, Goldstein P, Armstrong PW et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: The Assessment of the Safety and Efficacy of the New Thrombolitic Regimen (ASSENT)-3 PLUS randomised trial in acute myocardial infarction. Circulation 2003; 108: 135.

186.  Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results of all randomized trials of more than 1000 patients. Lancet 1994; 343: 311–22.

187.  ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17.187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.

188.  Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13–20.

189.  UpToDate online [Internet] version 15.3. Amlodipine. In: UpToDate, Rose BD (Editors), UpToDate, Waltham, MA, 2007. [cited 2007 Dec 8]. Available from: <http://www.utdol.com/utd/content/search.do?search=amlodipine&searchOffset=0&source=MISSPELL>.

190.  Sociedade Brasileira de Cardiologia; Sociedade Brasileira de Hipertensão; Sociedade Brasileira de Nefrologia. V Diretrizes Brasileiras de Hipertensão Arterial. 2006. [Citado 2007 ago. 24]. Disponível em: <http://publicacoes.cardiol.br/consenso/2006/VDiretriz-HA.pdf>.

191.  Mumme A, Kemen M, Homann HH, Zumtobel V. The temperature dependence of fibrinolysis with streptokinase. Dtsch Med Wochenschr 1993 Nov 5;118(44):1594-6.

192.  Brogden RN, Speight TM, Avery GS. Streptokinase: a review of its clinical pharmacology, mechanism of action and therapeutic uses. Drugs 1973;5(5):357-45.

193.  Strife JL, Ball WS Jr, Towbin R, Keller MS, Dillon T. Arterial occlusions in neonates: use of fibrinolytic therapy. Radiology 1988 Feb;166(2):395-400.

194.  Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: A Meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166:2307-13.

195.  UpToDate online [Internet] version 15.3. Simvastatin. In: UpToDate, Rose BD, editors, UpToDate, Waltham, MA, 2007. [cited 2007 Dec 8]. Available from: <http://www.utdol.com/utd/content/search.do?search=simvastatin&searchOffset=0&source=MISSPELL>.

196.  Fuchs FD. Fármacos anti-hipertensivos. In: Fuchs, FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004: 668-83.

197.  Williams B. Evolution of hypertensive disease: a revolution in guidelines. Lancet 2006;368(9529):6-8.

198.  Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy (Cochrane Review). In: The Cochrane Library, Issue 2; 2004. Oxford: Update Software.

199.  The ALLHAT Of.cers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-97.

200.  Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49 (4):839-45.

201.  Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47(3): 352-8.

202.  Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366 (9496):1545-53.

203.  Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J. Beta-blockers for hypertension (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

204.  Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24 (11): 2131-41.

205.  Cruickshank JM. New guidelines on hypertension. Lancet 2006; 368 (9536): 641. [Letter]

206.  Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

207.  Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364 (9446): 1684-9.

208.  Dahlöf B, Devereux RB, Kjeldsen SE, Lyle PA, Zhang Z, Edelman JM. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future? Blood Press 2007; 16 (1): 6-12.

209.  Wilkinson IB, McEniery CM, Cockcroft JR. Atenolol and cardiovascular risk: an issue close to the heart. Lancet 2006; 367: 627-8.

210.  Wannmacher L. Manejo da hipertensão na gravidez: o pouco que se sabe. In: OPAS. Uso racional de medicamentos Temas Selecionados. Brasília; 2004. [OPAS, v. 1 n. 11]

211.  Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

212.  UpToDate online [Internet] version 15.3. Methyldopa. In: UpToDate, Rose BD, editors, UpToDate, Waltham, MA, 2007. [Cited 2007 Dec 8]. Available from: <http://www.utdol.com/utd/content/search.do?search=methyldopa&searchOffset=0&source=MISSPELL>.

213.  Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy (Cochrane Review). In: The Cochrane Library, Issue 3, 2007. Oxford: Update Software.

214.  Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, et al; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006; 48 (3):374-84.

215.  Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290 (21): 2805-16.

216.  Blood Pressure Lowering Treatment Triallists´Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1955-64.

217.  Estacio RO, Barriet W, Jeffers MS, Hiatt WB, Biggerstaff SL, Gifford N, Schrier RW. The effect of Nisoldipine as compared with Enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645-52.

218.  Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21:597-603.

219.  Wright JT JR, Bakris G, Greeene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288:2421-31.

220.  Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GR, et al. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-92.

221.  Shankar PK, Vidyasagar S, Adiga S, Naidu MU, Usha Rani P, Rao D, et al. cy and tolerability of trandolapril in mild to moderate hypertension--a double blind comparative clinical trial with enalapril in Indian population. Indian J Physiol Pharmacol 2006; 50 (4): 421-6.

222.  Otero ML, Claros NM; Study Investigators Group. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. Clin Ther 2005; 27 (2):166-73.

223.  Papatsonis DN, Lok CA, Bos JM, Geijn HP, Dekker GA. Calcium channel blockers in the management of preterm labor and hypertension in pregnancy. Eur J Obstet Gynecol Reprod Biol 2001; 97:122-40.

224.  Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol 1993; 100: 959-61.

225.  Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003; 327:955-60.

226.  UpToDate online [Internet] version 15.3. sodium nitroprusside. In: UpToDate, Rose BD, editors, UpToDate, Waltham, MA, 2007. [Cited 2007 Dec 8]. Available from: <http://www.utdol.com/utd/content/search.do?search=sodiumnitroprusside&searchOffset=0&source=MISSPELL>.

227.  Pitt B, Zannad F, Remme WJ, Cody R, Castaignr A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999: 341:709-17.

228.  Guglin M, Awad KE, Polavaram L, Vankayala H. Aldosterone antagonists: the most underutilized class of heart failure medications. Am J Cardiovasc Drugs 2007; 7 (1): 75-9.

229.  Gao X, Peng L, Adhikari CM, Lin J, Zuo Z. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 2007; 13 (3):170-7.

230.  Chang SC, Chang HI, Chen FJ, Shiao GM, Wang SS, Lee SD. Therapeutic effects of diuretics and paracentesis on lung function in patients with non-alcoholic cirrhosis and tense ascites. J Hepatol 1997; 26:833-8.

231.  Fernández-Esparrach G, Guevara M, Sort P, Pardo A, Jiménez W, Ginès P, et al. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol 1997; 26:614-20.

232.  van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006; 24 (11): 2285-92.

233.  Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70 (12):2116-23.

234.  Salvador DRK, Rey NR, Ramos GC, Punzalan FER. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

235.  Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006; 333:420.

236.  Faris R, Flather MD, Purcell H, Poole-Wilson PA, Coats AJS. Diuretics for heart failure (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

237.  Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: systematic review and meta-analysis. JAMA 1997; 277:739-45.

238.  Neaton, JD; Grimm Jr, RH; Prineas, RJ et al. Treatment of mild hypertension Study (TOMHS): final results. JAMA 1993; 270:713-24.

239.  Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al; and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289 (19):2560-72.

240.  Mindell JA, Chertow GM. A practical approach in acute renal failure. Med Clin North Am 1997; 81:731-48.

241.  Wakai A, Roberts I, Schierhout G. Mannitol for acute traumatic brain injury (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

242.  Hinds C, Watson D. Manipulating hemodynamics and oxygen transport in critically ill patients. N Engl J Med 1995; 333:1074-5.

243.  Moraes RS, Fuchs FD. Fármacos usados em choque. In: Fuchs, FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a.. ed. Rio de Janeiro: Guanabara Koogan; 2004: 733-43.

244.  Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Eng J Med 1995; 333:1025-32.

245.  Lakobishvili Z, Hasdai D. Cardiogenic shock: treatment. Med Clin North Am 2007; 91 (4):713-27.

246.  Müllner M, Urbanek B, Havel C, Losert H, Waechter F, Gamper G. Vasopressors for shock (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software.

247.  Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen de-livery in the treatment of critically ill patients. N Eng J Med 1994; 330:1717-22.

248.  Dominguez-Rodriguez A, Samimi-Fard S, Garcia-Gonzalez MJ, Abreu-Gonzalez P. Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty. Int J Cardiol 2007 Jul 20; [Epub ahead of print]

249.  Samimi-Fard S, García-González MJ, Domínguez-Rodríguez A, Abreu-González P. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol 2007 Jul 20; [Epub ahead of print]

250.  Leclerc F, Sadik A. Is there still a place for dopamine in the paediatric critical care setting? Ann Fr Anesth Reanim 2007; 26 (6):576-580.

251.  UpToDate online [Internet] version 15.3. Dopamine. In: UpToDate, Rose BD (Editors), UpToDate, Waltham, MA, 2007. [cited 2007 Dec 8]. Available from: <http://www.utdol.com/utd/content/search.do?search=dopamine&searchOffset=0&source=MISSPELL>.

252.  Wannmacher L, Costa AF. Estatinas: uso racional na cardiopatia isquêmica. Brasília; 2004. (OPAS, v. 1, n. 10]

253.  Reinhardt SC, Vaughan CJ. Statins in acute coronary syndromes. Drugs Today Barc 2002; 38: 339-50.

254.  LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A metaanalysis of randomized controlled trials. JAMA 1999; 282:2340-6.

255.  Vijan S, Hayward RA. Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians. Ann Intern Med 2004; 140 (8): 650-8.

256.  Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other highrisk conditions. J Vasc Surg 2007; 45 (4):645-54.

257.  Heart Protection Study Collaborative Group. Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002; 360:7–22.

258.  Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-92.

259.  Costa J, Borges M, , David C, Carneiro AV. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006; 332:1115-24.

260.  Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360 (9326): 7-22.

261.  Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990; 2: 392-5.

262.  Taylor MJ, Carney S, Geddes J, Goodwin G. Folate for depressive disorders (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

263.  Malouf R, Grimley Evans J, Areosa Sastre A. Folic acid with or without vitamin B12 for cognition and dementia (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

264.  Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

265.  Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

266.  McDonald SD, Ferguson S, Tam L, Lougheed J, Walker MC. The prevention of congenital anomalies with periconceptional folic acid supplementation. J Obstet Gynaecol Can 2003; 25: 115-21.

267.  Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, Vale L, Wallace S, MacLeod A. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.To assess the effects of rHu EPO use in pre-dialysis patients with renal anaemia.

268.  Cody J, Daly C, Campbell M, Donaldson C, Khan I, Vale L, Wallace S, MacLeod A. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

269.  Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

270.  Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

271.  Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. Am J Hypertens 2000; 13:105-10.

272.  Friel JK, Aziz K, Andrews WL, Harding SV, Courage ML, Adams RJ. A doublemasked, randomized control trial of iron supplementation in early infancy in healthy term breast-fed infants. J Pediatr 2003; 143:582-6.

273.  Reveiz L, Gyte GML, Cuervo LG. Treatments for iron-deficiency anaemia in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

274.  Dodd J, Dare MR, Middleton P. Treatment for women with postpartum iron deficiency anaemia (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

275.  Pena-Rosas JP, Viteri FE. Effects of routine oral iron supplementation with or without folic acid for women during pregnancy (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

276.  Rohde LE, Fuchs FD, Picon PD. Antitrombóticos. In: Fuchs, FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da ferapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004: 684-704.

277.  Smith SF, Biggs MT, Sekhon LH. Risk factors and prophylaxis for deep venous thrombosis in neurosurgery. Surg Technol Int 2005;14: 69-76.

278.  Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296 (8):935-42.

279.  Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130 (10): 800-9.

280.  Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, et al. Low-molecular weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med 2000; 160:229-36.

281.  Ozgonenel B, O’malley B, Krishen P, Eisenbrey AB. Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital. Am J Hematol 2007 Aug 2; [Epub ahead of print]

282.  Goldhaber SZ. Pulmonary embolism. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald´s Heart Disease. 7th. ed. Philadelphia: Elsevier Saunders; 2005: 1789-806.

283.  Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2001; 38:1231-66.

284.  Massel D, Little SH. Risks and Benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J Am Coll Cardiol 2001;37: 569-78.

285.  Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL et al, for the Warfarin–Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1493-5.

286.  Keller T, Squizzato A, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005158.

287.  Caprie Steering Committee. A randomised, blinded trialof clopidogrel versus aspirin in patients in risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329.

288.  Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355:1295-302.

289.  Hankey GJ, Eikelboom JW. Aspirin for the primary prevention of cardiovascular events. Benefits depend on the patient’s absolute cardiovascular and bleeding risks. MJA 2002; 177:343-344.

290.  International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997; 349:1569-81.

291.  CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke. Lancet 1997; 349:49.

292.  Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

293.  Hedner U, Brun NC. Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent. Neuroradiology 2007; [Epub ahead of print]

294.  Quintana Díaz M, Sánchez Casado M, García de Lorenzo Y Mateos A. Recombinant activated Factor VII. Med Intensiva 2007; 31 (6): 326-30.

295.  Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

296.  Hind D, Lloyd-Jones M, Makris M, Paisley S. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

297.  Marti-Carvajal AJ, Salanti G, Marti-Carvajal PI. Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

298.  Lewis SJ, Stephens E, Florou G, Macartney NJ, Hathaway LS, Knipping J, Collins PW. Measurement of global haemostasis in severe haemophilia A following factor VIII infusion. Br J Haematol 2007; [Epub ahead of print]

299.  Ruggeri ZM. Von Willebrand factor: Looking back and looking forward. Thromb Haemost 2007; 98 (1):55-62.

300.  Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM; For The Rits-Fitnhes Study Group. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13 (4): 373-9.

301.  Franchini M, Veneri D, Lippi G. Inherited factor XI deficiency: a concise review. Hematology 2006; 11(5): 307-9.

302.  Salomon O, Seligsohn U. New observations on factor XI deficiency. Haemophilia 2004; 109 (Suppl 4): 184-7.

303.  Junagade P, Grace R, Gover P. Fixed dose prothrombin complex concentrate for the reversal of oral anticoagulation therapy. Hematology 2007 Jun 20:1. [Epub ahead of print]

304.  Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2007 Aug 29; [Epub ahead of print]

305.  Jardine LA, Jenkins-Manning S, Davies MW. Albumin infusion for low serum albumin in preterm newborn infants (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

306.  The Albumin Reviewers (Alderson P, Bunn F, Li Wan Po A, Li L, Roberts I, Schierhout G). Human albumin solution for resuscitation and volume expansion in critically ill patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

307.  Alderson P, Bunn F, Li Wan Po A, Li L, Roberts I, Schierhout G. Human albumin solution for resuscitation and volume expansion in critically ill patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

308.  WHO Expert Committee on the Selection and Use of Essential Medicines. The Selection and Use of Essential Medicines: report of the WHO Expert Committee, 2005: 21 [WHO Technical Report Series; 933]

309.  Roberts I, Alderson P, Bunn F, Chinnock P, Ker K, Schierhout G. Colloids versus crystalloids for fluid resuscitation in critically ill patients (Cochrane Review). In: The Cochrane Library, Issue 1, 2007. Oxford: Update Software.

310.  Bunn F, Alderson P, Hawkins V. Colloid solutions for fluid resuscitation (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

311.  Lorenz W, Duda D, Dick W, Sitter H, Doenicke A, Black A, Weber D, Menke H, Stinner B, Junginger T, et al. Incidence and clinical importance of perioperative histamine release: randomised study of volume loading and antihistamines after induction of anaesthesia. Lancet 1994; 343:933-40

312.  Perlroth DJ, Sanders GD, Gould MK. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Arch Intern Med 2007; 167 (1): 74-80.

313.  Kunamneni A, Abdelghani TT, Ellaiah P. Streptokinase--the drug of choice for thrombolytic therapy. J Thromb Thrombol 2007; 23 (1): 9-23.

314.  Grupo Italiano per Lo Studio Della Streptochinase Nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolitic therapy in acute myocardial infarction. Lancet 1986; 1:97-402.

315.  Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

316.  Rostom A, Wells G, Tugwell P, Welch V, Dubé C, McGowan J. The prevention of chronic NSAID induced upper gastrointestinal toxicity: A Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 2000; 27:2203-14.

317.  Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, van Rensburg J, et al for the Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 12: 719-26.

318.  Ell C, Schoerner C, Solbach W, Stolte M, Vieth M, et al. and the AMOR Study Group. The AMOR Study: a randomized, double-blinded trial of omeprazole versus ranitidine together with amoxycillin and metronidazole for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2001; 13:685-91.

319.  Coelho LC, Léon-Barúa R, Quigley E and representatives of the Latin-American National Gastroenterological Societies affiliated with the Inter-American Associations of Gastroenterology (AIGE). Latin-American Consensus Conference on Helicobacter pylori Infection. Am J Gastroenterol 2000; 95:2688-91.

320.  American Society of Health-System Pharmacists. ASHP therapeutic position statement on the identification and treatment of Helicobacter pylori-associated peptic ulcer disease in adults. Am J Health Syst Pharm 2001; 58: 331-7.

321.  Malfertheiner P, Mégraud F, O´Morain C, Hungins AP, Jones R and The European Helicobacter pylori Study Group. Current concepts in the management of Helicobacter pylori infection – The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16:167-80.

322.  British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 54th. ed. London: BMJ Publishing Group and APS Publishing; 2007. Available from: <http://www.bnf.org>.

323.  Eriksson S, Langstrom G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesaphagitis: a meta-analysis. Eur J Gastroenterol Hepatol 1995; 7:467-75.

324.  Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocellá L, Pera A. Effectivenes of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002; 16:1269-75.

325.  Rostom A, Wells G, Tugwell P, Welch V, Dubé C, McGowan J. The prevention of chronic NSAID induced upper gastrointestinal toxicity: A Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 2000; 27:2203-14.

326.  Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence based appraisal of reflux disease management – the Genval Workshop Report. Gut 1999; 44 (Suppl 2): S1-S16.

327.  Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptoms relief in grade II to IV gastroesophageal reflux disease: a metaanalysis. Gastroenterology 1997; 112:1798-810.

328.  Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al for the Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338:727-34.

329.  Suerbaum S, Michetti P. Medical Progress: Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86.

330.  Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

331.  Malfertheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G; European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16:167-80.

332.  Brandão ABM. Antieméticos. In: Fuchs, FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004:801-13.

333.  Alhashimi D, Alhashimi H, Fedorowicz Z. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

334.  Patterson D, Abell T, Rothstein R, Koch K. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999; 94:1230-4.

335.  Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs metoclorpramide + dexamethasone + diphenhydramine in prevention of cisplatin induced emesis. Lancet 1992;340:96-9.

336.  Roila F, Ballatori E, Tonato M, Del Favero A. 5-HT3 receptor antagonists: differences and similarities. Eur J Cancer 1997; 33:1364-70.

337.  del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting. Results of a meta-analysis of randomized controlled trials. Cancer 2000; 89:2301-8.

338.  Domino KB, Anderson EA, Polissar NL, Posner KL. Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anesth Analg 1999; 88:1370-9.

339.  Brandão ABM. Laxativos e antidiarréicos. In: Fuchs FD, Wannmacher L & Ferreira MBC (Eds). Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004: 814-23.

340.  Baqui AH, Ahmed T. Diarrhoea and malnutrition in children. Replacing fluid and minerals, particularly zinc, remains vital. BMJ 2006; 332:78. [Editorial]

341.  Hanauer SB, DuPont HL, Cooper KM, Laudadio C. Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamida alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr Med Res Opin 2007; 23(5):1033-43.

342.  Wang HH, Shieh MJ, Liao KF. A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults. World J Gastroenterol 2005; 11 (10):1540-3.

343.  Fuchs FD, Wannamacher L, Ferreira MBC, editors. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004. 1074 p.

344.  Jones MP, Talley NJ, Nuyts G, Dubois D. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci 2002; 47: 2222-30.

345.  Wannmacher L Constipação intestinal crônica no adulto e na criança: quando não se precisa de medicamentos. In: OPAS. Uso Racional de Medicamentos Temas Selecionados. Brasília; 2005. [OPAS, volume 3, número 1]

346.  Ramkumar D, Rao SSC. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005; 100: 936-71.

347.  McEvoy GK editor. AHFS Drug Information. Bethesda, MD: ASHP, 2005.

348.  Schiller LR. Review article: the therapy of constipation. Aliment Pharmacol Ther 2001; 15: 749-56.

349.  Taketomo C K, Hodding JH, Kraus DM. Pediatric dosage handbook. 12th. ed. Hudson: Lexi-comp; 2005.

350.  Psyllium. In: Farmacopéia Portuguesa [Portuguese pharmacopeia]. 7a. ed. Lisboa: Infarmed; 2002. vol. 2, p.721-2. Portuguese.

351.  Wright G, Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007; 21(1): 95-110.

352.  Lederle FA, Busch DL, Mattox KM, West MJ, Aske DM. Cost-effective treatment of constipation in the elderly: A randomized double-blind comparison of sorbitol and lactulose. Am J Med 1990; 89: 597-601.

353.  Rees J. Asthma control in adults. BMJ 2006; 332:767-71.

354.  Walters EH, Walters J, Gibson P, Jones PW. Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

355.  Bisgard H, Szefler S. Long acting b2 agonists and paediatric asthma. Lancet 2006; 367: 286-8.

356.  Salpeter, SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-Analysis: Effect of Long-Acting [beta]-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths. Ann Intern Med 2006; 144 (12): 904-12.

357.  Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The salmeterol multicenter asthma research trial. Chest 2006; 129: 15-26.

358.  Mash B, Bheekie A, Jones PW. Inhaled versus oral steroids for adults with chronic asthma (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

359.  Adams N, Bestall JM, Lasserson TJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

360.  Stelmach R, do Patrocinio T Nunes M, Ribeiro M, Cukier A. Effect of treating allergic rhinitis with corticosteroids in patients with mild-to-moderate persistent asthma. Chest 2005; 128 (5): 3140-7.

361.  Townshend J, Hails S, Mckean M. Management of asthma in children. BMJ 2007; 335: 253-7.

362.  Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998; 339: 1030-5.

363.  Qureshi F, Zaritsky A, Lakkis H. Efficacy of nebulized ipratropium in severely asthmatic children. Ann Emerg Med 1997; 29: 205-11.

364.  Lin RY, Pesola GR, Bakalchuk L, Morgan JP, Heyl GT, Freyberg CW, et al. Superiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adult asthma: a randomized clinical trial. Ann Emerg Med 1998; 31:208-13.

365.  Stoodley RG, Aaron SD, Dales RE. The role of ipratropium bromide in the emergency management of acute asthma exacerbation: a meta-analysis of randomized clinical trials. Ann Emerg Med 1999; 34:8-18.

366.  Rodrigo J, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Resp Crit Care Med 2000; 161:1862-8.

367.  Rodrigo GJ, Rodrigo C. The Role of anticholinergics in acute asthma treatment. Chest 2002; 121:1977-87.

368.  Plotnick LH, Ducharme FM. Combined inhaled anticholinergics and beta2-agonists for initial treatment of acute asthma in children (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

369.  Browne GJ, Trieu L, Van Asperen P. Randomized, double-blind, placebo controlled trial of intravenous salbutamol and nebulized ipratropium bromide in early management of severe acute asthma in children presenting to an emergency department. Crit Care Med 2002; 30: 448-53.

370.  Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

371.  McDonald NJ, Bara AI, McKean M. Anticholinergic therapy for chronic asthma in children over two years of age (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

372.  National Asthma Education and Prevention Program. Expert panel report 2: Guidelines for the diagnosis and treatment of asthma. Bethesda, MD: National Institutes of Health; April 1997. [Publication No. 97-4051].

373.  Cates C. Chronic asthma. BMJ 2001; 323: 976-9.

374.  Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

375.  Edmonds ML, Camargo CA, Pollack CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

376.  Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalised patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

377.  Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

378.  World Health Organization (WHO) and National Heart, Lung, and Blood Institute (U.S.) (NHLBI). Global Initiative for Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; 1995 (revised 1998). 249 p.

379.  British Thoracic Society. Guidelines on the management of asthma. Thorax 1993; 48 (Suppl): 1-248.

380.  Amitabha C, Rakesh L, Pandey RM, Kabra SK. Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. The Indian J Pediatr 2006; 73 (11): 979-83.

381.  Dennis RJ, Solarte I, FitzGerald JM. Acute asthma treatments. BMJ Clinical Evidence [online] 2006 Aug [cited 2007 May 25]. Available from: <http://www.clinicalevidence. com/ceweb/conditions/rdc/1501/1501.jsp>.

382.  Klasco RK, editor. USP DI. Advice for the Patients [Database on the Internet]. Greenwood Village (Colorado): Thomson MICROMEDEX; 1974-2006. [Cited 2007 May 5]. Available form: <http://www.periodicos.capes.gov.br>.

383.  Keeley D, McKean M. Asthma and other wheezing disorders in children. BMJ Clinical Evidence [online] 2007 Feb [cited 2007 May 25]. Available from: <http://clinicalevidence.bmj.com/ceweb/conditions/chd/0302/0302.jsp>.

384.  Dennis RJ, Solarte I, FitzGerald JM. Asthma: acute asthma treatments. BMJ Clinical Evidence [online] 2007 Feb [cited 2007 May 25]. Available from: <http://clinicalevidence.bmj.com/ceweb/conditions/rdc/1501/1501_I4.jsp>.

385.  Dennis RJ, Solarte I, FitzGerald JM. Asthma: Chronic asthma treatments. BMJ Clinical Evidence [online] 2007 Feb [cited 2007 May 25]. Available from: <http://clinicalevidence.bmj.com/ceweb/conditions/rdc/1501/1501_I1.jsp>.

386.  Kerstjens H, Postma D, ten Hacken N. Chronic obstructive pulmonary disease. BMJ Clinical Evidence [online] 2007 Feb [cited 2007 May 25]. Available from: <http://clinicalevidence.bmj.com/ceweb/conditions/rdc/1502/1502_I3.jsp>.

387.  Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

388.  National Institutes of Health Consensus Development Panel. Antenatal corticosteroids revisited: repeated courses – National Institutes of Health Consensus Development Conference Statement, August 17-18, 2000. Obstet Gynecol 2001; 98:144-50.

389.  Crowther CA, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

390.  Elimian A, Garry D, Figueroa R, Spitzer A, Wiencek V, Quirk JG. Antenatal betamethasone compared with dexamethasone (betacode trial): a randomized controlled trial. Obstet Gynecol 2007;110 (1):26-30.

391.  Harding JE, Pang J, Knight DB, Liggins GC. Do antenatal corticosteroids help in the setting of preterm rupture of membranes? Am J Obstet Gynecol 2001; 184: 131-9.

392.  Sinha S, Moya F, Donn SM. Surfactant for respiratory distress syndrome: are there important clinical differences among preparations? Curr Opin Pediatr 2007; 19 (2):150-4.

393.  Robrts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No. CD004454. DOI: 10.1002/14651858.CD004454.pub2.

394.  Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

395.  Parker KL, Schimmer BP. Pituitary hormones and their hypothalamic releasing hormones. In: Brunton LL, Lazxo JS, Parker KL, eds. Goodman & Gilman´s the pharmacological basis of therapeutics. 11th. ed. New York: McGraw-Hill; 2006:1489-510.

396.  Farwell AP, Braverman LE. Thyroid and antithyroid drugs. In: Brunton LL, Lazxo JS, Parker KL, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th. ed. New York: McGraw-Hill; 2006: 1511-40.

397.  Branchtein L, Matos MCG. Fármacos e tireóide. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004:876-85.

398.  LaFranchi SH, Austin J. How should we be treating children with congenital hypothyroidism? J Pediatr Endocrinol Metab 2007; 20 (5): 559-78.

399.  Salerno M, Militerni R, Bravaccio C, Micillo M, Capalbo D, Di MS, Tenore A. Effect of Different Starting Doses of Levothyroxine on Growth and Intellectual Outcome at Four Years of Age in Congenital Hypothyroidism. Thyroid 2002; 12 (1):45-52.

400.  Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab 2007; 92 (6): 2157-62.

401.  Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab 2001; 86: 2354-9.

402.  Davies TF, Larsen PR. Thyrotoxicosis. In: Larsen PR, Krononberg HM, Melmed S, Polonsky KS, eds. Williams’ textbook of endocrinology. 10th. ed. Philadelphia: W.B. Saunders; 2003: 374-421.

403.  Ngo AS, Lung Tan DC. Thyrotoxic heart disease. Resuscitation 2006; 70 (2): 287-90.

404.  Wareham NJ, O´Rahilly S. The changing classification and diagnosis of diabetes.

1.        New classification is based on pathogenesis, not in insulin dependence. BMJ 1998; 317:359-60.

405.  Wannmacher L. Antidiabéticos orais: comparação entre diferentes intervenções. In: OPAS. Uso Racional de Medicamentos Temas Selecionados. Brasília; 2005. [OPAS, v. 2, n. 11].

406.  Campbell A. Glycaemic control in type 2 diabetes. BMJ Clinical Evidence. [Web publication date: 01 Jul 2006 (based on June 2005 search)]

407.  Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.

408.  UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33) Lancet 1998; 352: 837-53.

409.  Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001; 358: 739-46.

410.  Nathan DM. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. Lancet 1998; 352:832-3.

411.  British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 52nd. ed. London: BMJ Publishing Group and RPS Publishing; September 2006. Available from: <http://www.bnf.org/bnf/bnf>.

412.  Crespí-Monjo M, Delgado-Sánchez O, Ventayol-Bosch P, Lafuente-Fló A, Pinteñoblanco M, Escrivá-Torralva A, Puigventóslatorre F, Martínez-López I. Estudio prospectivo y aleatorizado de intercambio terapéutico de sulfonilureas en pacientes con diabetes mellitus tipo 2. Farm Hosp (Madrid) 2004; 28 (6):426-32.

413.  Lindberg G, Lindblad U, Melander A. Sulphonylureas for treating type 2 diabetes mellitus (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 1, 2006. Oxford: Update Software.

414.  Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004; 64 (12): 1339-58.

415.  Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, et al. Threeyear mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22(6):477-82.

416.  Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E, Marchionni N, Mannucci E. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007 Mar 23; [Epub ahead of print]

417.  UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. (UKPDS 34) Lancet 1998; 352: 854-65.

418.  Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

419.  Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

420.  Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now? Lancet 2005; 366(9483):409-21.

421.  Wannmacher L, Lubianca JN. Terapia de reposição hormonal na menopausa: Evidências atuais. In: OPAS. Uso Racional de Medicamentos Temas Selecionados. Brasília; 2004. [OPAS, v.1, n. 6].

422.  Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q. Long term hormone therapy for perimenopausal and postmenopausal women (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

423.  Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

424.  Weiderpass E, Baron JA, Adami HO, Magnusson C, Lidgren A, Correia N, Persson I. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999; 353: 1824-8.

425.  Klasco RK, editor. DRUGDEX System [Database on the Internet]. Drug evaluations (Estrogens). Greenwood Village (Colorado): Thomson MICROMEDEX; 1974-2006. [Cited 2006 Jun 5]. Available form: <http://www.periodicos.capes.gov.br>.

426.  Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the Hormones and Urogenital Therapy Committee. Obstetric Gynecol 1998; 92(4):722-7.

427.  Palmer D. Prescribing and the menopause: regimens for hormone replacement therapy. [Citado 2007 jul 30] Disponível em <http://www.australianprescriber.com/magazine/17/1/13/6/>.

428.  Kuhl, H. Pharmakologie von Sexualsteroiden. Der Gynäkologe 1998; 31(10):832-47.

429.  Reilly CH et al (eds.) Drug Facts and Comparisons 2005. 59th. ed. Saint Louis, (Missouri): Wolters Kluwer Health; 2005: 262-8.

430.  Schmidt JW, Wollner D, Curcio J, Riedlinger J, Kim LS. Hormone replacement therapy in menopausal women: Past problems and future possibilities. Gynecol Endocrinol 2006; 26 (10):564-77.

431.  Liewertz RW. Pharmacology and pharmacokinetics of estrogens. Am J Obstet Gynecol 1987; 156(5):1289-93.

432.  Van Gorp T, Neven P. Endometrial safety of hormone replacement therapy: review of literature. Maturitas 2002; 42:93–104.

433.  Jewelewicz R. New developments in topical estrogen therapy. Fertil Steril 1997; 67(1):1-12.

434.  Bachmann G. The estradiol vaginal ring: a study of existing clinical data. Maturitas 1999; 22:S21-S29.

435.  Casper F, Petri E, Vaginal Ring Study Group. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Int Urogynecol J 1999; 10:171-6.

436.  Drug Interactions. Substractes. Version 4.0 [AUG 2007]. Updated 2007 Nov 29. [Cited 2007 Ago 01]. Disponível em: <http://medicine.iupui.edu/flockhart/table.htm>.

437.  Haspels AA, Luisi M, Kicovic PM. Endocrinological and clinical investigation in postmenopausal women following administration of vaginal cream containing oestriol. Maturitas 1981; 3: 321-7.

438.  Vooijs GP, Geurts TBP. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol 1995: 62 (1):101–6.

439.  Morris E, Rymer J. Menopausal symptoms. In: BMJ Clinical Evidence. [Web publication date: 01 Jul 2006 (based on December 2005 search) ]

440.  Focan C, Beauduin M, Majois F, Canon J-L, Cusumano G, Focan-Henrard D, Lobelle J-P, for the Adjuvant Breast Cancer Project, Belgium. High-Dose Oral Medroxyprogesterone Acetate or Tamoxifen as Adjuvant Hormone Therapy for Node-Negative Early-Stage Breast Cancer: Randomized Trial with 7-Year Update. Clin Breast Cancer 2004; 5:136-41.

441.  von Minckwitz G, Loibl S, Brunnert K, Kreienberg R, Melchert F, Mösch R, et al., for the South West German Gynecologic Oncology Group (SWGGOG). Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer—a multicentre, open, controlled, prospectively randomised trial. Eur J Cancer 2002; 38: 2265-71.

442.  Chlebowski RT, Wactawski-Wende J,Ritenbaugh C,HubbellFA, Ascensao J, Rodabough RJ, et al., for the Women’s Health Initiative Investigators. Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women. N Engl J Med 2004; 350: 991-1004.

443.  Civitelli R, Pilgram TK, Dotson M, Muckerman J, Lewandowski N, Armamento-Villareal R, et al. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2002; 162:1409-15.

444.  Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287:2668-76.

445.  Greendale GA, Wells B, Marcus R, Barrett-Connor E. How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial. Arch Intern Med 2000; 160: 3065-71.

446.  Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89:503-10.

447.  Bashin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000; 283:763-70.

448.  Amory JK, Page ST, Bremner WJ. Drug insight: Recent advances in male hormonal contraception. Nat Clin Pract Endocrinol Metab 2006; 2 (1):32-4.

449.  Trussell J, Vaughan B. Method-Related Discontinuation and Resumption of Use: Results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999; 31 (2): 64-72,93.

450.  Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998; 30 (1):24–29,46.

451.  Lubianca JN, Wannmacher L.Contraceptivos Orais. In: Fuchs FD, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan, 2004: 855-66.

452.  Shulman LP, Nelson AL, Darney PD. Recent developments in hormone delivery systems. Am J Obstet Gynecol 2004; 190 (4 suppl 1): S39-S48.

453.  Wannmacher L. Novas opções contraceptivas. In: OPAS. Uso Racional de Medicamentos Temas Selecionados. Brasília; 2006. [OPAS 2006. v. 3, n. 7]

454.  Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 131-4.

455.  Vliet HAAM, Grimes DA, Lopez LM, Schulz KF, Helmerhorst FM. Triphasic versus monophasic oral contraceptives for contraception (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

456.  Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

457.  American Academy of Pediatrics. Committee on Adolescence. Emergency contraception (Policy Statement). Pediatrics 2005; 116(4):1026-35.

458.  von Hertzen H et al; WHO Research Group on Post-ovulatory Methods of Fertility Regulation. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360:1803-10.

459.  Cheng L, Gülmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Look PFA. Interventions for emergency contraception (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

460.  Wannmacher L. Contracepção de emergência: evidências versus preconceitos. In: OPAS. Uso Racional de Medicamentos Temas Selecionados. Brasília; 2005. [OPAS, v. 2, n. 6].

461.  Polis CB, Schaffer K, Blanchard K, Glasier A, Harper CC, Grimes DA. Advance provision of emergency contraception for pregnancy prevention (full review) (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

462.  Truitt ST, Fraser A, Gallo MF, Lopez LM, Grimes DA, Schulz KF. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

463.  Loose DS, Stancel GM. Oestrogens and progestins. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman´s the pharmacological basis of therapeutics. 11th. ed. New York: McGraw-Hill, 2006: 1541-71.

464.  von Hertzen H, Piaffio G, Ding J, Chen J, Song S, Bartfai G, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002, 360:1803-10.

465.  Boletin médico de IPPF: recomendación del IMAP sobre la dosis única de levonorgestrel para la anticoncepción de emergencia, junho 2003; 37(30). In: Aldrighi JM, Petta CA, eds. Anticoncepção: aspectos contemporâneos. São Paulo: Atheneu; 2005. 224 p.

466.  Lubianca JN, Wannmacher L. Contraceptivos orais. In: Fuchs Fd, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004. 1074 p.

467.  Draper BH, Morroni C, Hoffman M, Smit J, Beksinska M, Hapgood J, Merwe L. Depot medroxyprogesterone versus Norethisterone oenanthate for long-acting progestogenic contraception (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

468.  Cromer BA, Lazebnik R, Rome E, Stager M, Bonny A, Ziegler J, Debanne SM. Doubleblinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol 2005; 192 (1): 42-7.

469.  Gallo MF, Grimes DA, Schulz KF, d’Arcangues C, Lopez LM. Combination injectable contraceptives for contraception (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

470.  Hall PE. New once-a-month injectable contraceptives, with particular reference to Cyclofem/Cyclo-Provera. Int J Gynaecol Obstet 1998; 62 (Suppl 1): S43-S56.

471.  Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

472.  Aedo AR, Landgren BM, Johannisson E, Diczfalusy E. Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. Contraception 1985; 31:453-69.

473.  Oriowo MA, Landgren B-M, Stenström B, Diczfalusy E. A comparison of the pharmacokinetic properties of three estradiol esters. Contraception 1980; 21:415-24.

474.  Bassol S, Hernandez C, Nava MP, Trujillo AM, Luz de la Cruz D. A comparative study on the return to ovulation following chronic use of once-a-month injectable contraceptives. Contraception 1995; 51: 307-11.

475.  Bassol S, Craviotto MC, Durand M, Bailon R, Carranza S, Fugarolas J et al. Mesigyna. Once-A-Month Combined Injectable Contraceptive: Experience in Latin America. Contraception 2000; 61:309-16.

476.  Tiras MB, Noyan V, Fener N, Guner H, Yildirim M, Darney PD. Effects of a monthly injectable steroidal contraceptive, Mesigyna, on menstrual pattern, lipoproteins, and coagulation parameters. Contraception 2001; 63:151–3.

477.  Guazzelli CAF, Jacobucci MSBM, Barbieri M, Araújo FF, Moron AF. Monthly injectable contraceptive use by adolescents in Brazil: evaluation of clinical aspects. Contraception 2007; 76:45–8.

478.  United Nations Development Programme, United Nations Population Fund, World Health Organization and World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation. Comparative study of the effects of two once-a-month injectable contraceptives (Cyclofem® and Mesigyna®) and one oral contraceptive (Ortho-Novum 1/35®) on coagulation and fibrinolysis. Contraception 2003; 68:159-76.

479.  Hughes E, Brown J, Collins J, Vandekerckhove P. Clomiphene citrate for unexplained subfertility in women (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

480.  Beck JI, Boothroyd C, Proctor M, Farquhar C, Hughes E. Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

481.  Al-Inany H. Female infertility. BMJ clinical Evidence. [Web publication date: 01 Nov 2005 (based on April 2004 search)]

482.  McDonald S, Abbott JM, Higgins SP. Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

483.  Prendiville WJ, Elbourne D, McDonald S. Active versus expectant management in the third stage of labour (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

484.  Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam QM. Prophylactic use of ergot alkaloids in the third stage of labour (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

485.  King JF, Flenady VJ, Papatsonis DNM, Dekker GA, Carbonne B. Calcium channel blockers for inhibiting preterm labour (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

486.  Obrien WF. Cervical ripening and labor induction: progress and changes. Clin Obst Gynecol 1995 38: 221-3.

487.  Shyken JM, Petrie RH. Oxytocine to induce labor. Clin Obst Gynecol 1995; 38: 232-45.

488.  Kelly AJ, Tan B. Intravenous oxytocin alone for cervical ripening and induction of labour (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

489.  Cotter A, Ness A, Tolosa J. Prophylactic oxytocin for the third stage of labour (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

490.  Lubianca, JN. Contratores e relaxantes uterinos. In: Fuchs Fd, Wannmacher L, Ferreira MBC, eds. Farmacologia clínica: fundamentos da terapêutica racional. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2004. 1074 p.

491.  European Multicentre Study Group for Cabergoline in Lactation Inhibition. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. BMJ 1991; 302:1367-71.

492.  Recomendações para profilaxia da transmissão vertical do HIV e terapia antiretroviral em gestantes. Brasília, DF: Ministério da Saúde CN/DST AIDS; 2002-2003.

493.  Vilar L, Czepielewsk MA, Naves LA, Rollin GA, Casulari LA, Coelho CE. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr Pract 2007; 13(4):396-402.

494.  Pollice R, Di Giovambattista E, Tomassini A, Di Pucchio A, Mazza M, Di Michele V, Roncone R, Casacchia M. Risperidone-induced symptomatic hyperprolactinemia in youth with schizophrenia: efficacy and tolerability of cabergoline treatment. Clin Ter 2007; 158 (2):121-6.

495.  Meechan JG. Effective topical anesthetic agents and techniques. Dent Clin North Am 2002; 46(4):759-66.

496.  Nayak R, Sudha P. Evaluation of three topical anaesthetic agents against pain: a clinical study. Indian J Dent Res 2006; 17 (4):155-60.

497.  McMillan AS, Walshaw D, Meechan JG. The efficacy of Emla and 5% lignocaine gel for anaesthesia of human gingival mucosa. Br J Oral Maxillofac Surg 2000; 38 (1):58-61.

498.  Rigopoulos D, Gregoriou S, Kontochristopoulos G, Ifantides A, Katsambas A. Flutrimazole shampoo 1% versus ketoconazole shampoo 2% in the treatment of pityriasis versicolor. A randomised double-blind comparative trial. Mycoses 2007; 50 (3):193-5.

499.  Aggarwal K, Jain VK, Sangwan S. Comparative study of ketoconazole versus selenium sulphide shampoo in pityriasis versicolor. Indian J Dermatol Venereol Leprol 2003; 69 (2):86-7.

500.  Ratnavel RC, Squire RA, Boorman GC. Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatol Treat 2007; 18 (2):88-96.

501.  Lange DS, Richards HM, Guarnieri J, Humeniuk JM, Savin RC, Reyes BA, et al. Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 1998; 39 (6):944-50.

502.  Kuchenbecker Rösing CK.Quimioterapia antimicrobiana em Periodontia. In: Wannmacher L, Ferreira MBC, eds. Farmacologia clínica para dentistas. 3a. ed. Rio de Janeiro: Guanabara Koogan; 2007: 360-7.

503.  Nanda N, Michel RG, Kurdgelashvili G, Wendel KA. Trichomoniasis and its treatment. Expert Rev Anti Infect Ther 2006; 4 (1):125-35.

504.  Okun N, Gronau KA, Hannah ME. Antibiotics for bacterial vaginosis or Trichomonas vaginalis in pregnancy: a systematic review. Obstet Gynecol 2005; 105 (4): 857-68.

505.  Yoo J, Reid DC, Kimball AB. Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter? J Drugs Dermatol 2006; 5 (4):317-9.

506.  Conde JF, Yelverton CB, Balkrishnan R, Fleischer AB Jr, Feldman SR. Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol 2007; 6 (5):495-8.

507.  Joesoef MR, Schmid GP. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis 1999; 28 (suppl 1): S57–S65.

508.  Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol 2007; 196 (6):517-26.

509.  Riduan Joesoef MR, Schmid G. Bacterial vaginosis. In: BMJ Clinical Evidence. [Web publication date: 01 Apr 2005 (based on March 2004 search)]

510.  Ozturk MA, Gunes T, Koklu E, Cetin N, Koc N. Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. Mycoses 2006; 49 (6): 484-9.

511.  Normand S, François B, Dardé ML, Bouteille B, Bonnivard M, Preux PM, Gastinne H, Vignon P. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Med 2005; 31 (11):1508-13.

512.  Pankhurst CL. Candidiasis (oropharyngeal) . In: BMJ Clinical Evidence. [Web publication date: 01 Apr 2007 (based on June 2006 search)]

513.  Crawford F, Hart R, Bell-Syer S, Torgerson D, Young P, Russell I. Topical treatments for fungal infections of the skin and nails of the foot (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

514.  Brown D Jr, Henzl MR, LePage ME, et al. Butoconazole vaginal cream in the treatment of vulvovaginal candidiasis: comparison with miconazole nitrate and placebo. J Reprod Med 1986; 31:1045–8.

515.  Eichenfield LF, Bogen ML. Absorption and efficacy of miconazole nitrate 0.25% ointment in infants with diaper dermatitis. J Drugs Dermatol 2007; 6 (5):522-6.

516.  Spence D. Candidiasis (vulvovaginal). In: BMJ Clinical Evidence. [Web publication date: 01 Feb 2007 (based on October 2006 search)]

517.  Vermeulen H, Hattem JM, Storm-Versloot MN, Ubbink DT. Topical silver for treating infected wounds (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

518.  Charman C. Atopic eczema. BMJ 1999; 318: 1.600-4.

519.  Ramsay CA, Savoie JM, Gilbert M. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol 1996; 7 (Suppl 1): S15-S22.

520.  Bath-Hextall F, Williams H. Atopic eczema. In: BMJ Clinical Evidence. [Web publication date: 01 Jul 2006 (based on February 2005 search)]

521.  Luigi Naldi L, Rzany B. Psoriasis (chronic plaque). In: BMJ Clinical Evidence. [Web publication date: 01 Apr 2007 (based on July 2006 search)]

522.  Goodfield M, Kownacki S, Berth-Jones J. Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. J Dermatolog Treat 2004; 15 (1):14-22.

523.  Sharma V, Kaur I, Kumar B. Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis. Int J Dermatol 2003; 42 (10): 834-8.

524.  Swinkels OQ, Kucharekova M, Prins M, Gerritsen MJ, van der Valk PG, van de Kerkhof PC. The effects of topical corticosteroids and a coal tar preparation on dithranol-induced irritation in patients with psoriasis. Skin Pharmacol Appl Skin Physiol 2003; 16 (1):12-7.

525.  Buck Jr HW. Genital warts. In: BMJ Clinical Evidence. [Web publication date: 01 Aug 2006 (based on February 2007 search) ]

526.  Brasil. Agência Nacional de Vigilância Sanitária. Comissão Permanente de Revisão da Farmacopéia Brasileira. Subcomissão do Formulário Nacional. Resolução RDC Nº. 222, de 29 de julho de 2005. Diário Oficial da União, Brasília, DF.15 de agosto de 2005.

527.  Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos. Relação Nacional de Medicamentos Essenciais: Rename. 4ª. ed. Brasília, DF: Ministério da Saúde; 2006.

528.  Usha V, Gopalakrishnan Nair TV. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000; 42: 236–40.

529.  Burgess I. Head lice. In: BMJ Clinical Evidence. [Web publication date: 01 Apr 2007 (based on October 2006 search)]

530.  Johnstone P, Strong M. Scabies. [Web publication date: 01 Aug 2006 (based on March 2006 search).

531.  Mbah CJ. Studies on the lipophilicity of vehicles (or co-vehicles) and botanical oils used in cosmetic products. Pharmazie 2007; 62 (5):351-3.

532.  Agero AL, Verallo-Rowell VM. A randomized double-blind controlled trial comparing extra virgin coconut oil with mineral oil as a moisturizer for mild to moderate xerosis. Dermatitis 2004; 15 (3):109-16.

533.  Catterall WA, Mackie K. Local anesthetics. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman´s the pharmacological basis of therapeutics. 11th. ed. New York: McGraw-Hill; 2006:369-86.

534.  Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. 2005-2006. 13rd. ed. Hudson, Cleveland: Lexi-Comp; 2005:1332.

535.  Brocklehurst P, Rooney G. Interventions for treating genital chlamydia trachomatis infection in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

536.  Solomon AW, Mabey D, Mabey DCW. Trachoma. In: BMJ Clinical Evidence. [Web publication date: 01 Sep 2006 (based on January 2006 search)

537.  Mabey D, Fraser-Hurt N, Powell C. Antibiotics for trachoma (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

538.  Solomon AW et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004; 351(19):1962-70.

539.  Ejere H, Alhassan MB, Rabiu M. Face washing promotion for preventing active trachoma (Cochrane Review). In: The Cochrane Library, Issue 2, 2007. Oxford: Update Software.

540.  Bell TA, Grayston JT, Krohn MA, Kronmal RA. Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among newborns not at risk for gonococcal ophthalmitis. Eye Prophylaxis Study Group. Pediatrics 1993; 92:755-60.

541.  Napchan BM, Morales RP, Carvalho ML, Cunha KV, Figueras A. From suspicion to action: the chemical conjunctivitis and silver nitrate connexion example in Brazilian hospitals. Pharmacoepidemiol Drug Saf 2005; 14 (8):555-9.

542.  Henderer JD, Rapuano CJ. Ocular Pharmacology. In: Brunton LL, Lazo JS, Parker KLL, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th. ed. New York: McGraw-Hill; 2006: 1707-37.

543.  Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman: as bases farmacológicas da terapêutica. 10ª ed. Rio de Janeiro: McGraw-Hill. 2003. Seção XV, Capítulo 66, Farmacologia ocular; p. 1369-86.

544.  Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 1995; 113: 1009-16.

545.  Brasil. Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas. Tratamento do Glaucoma. Brasília, DF: Ministério da Saúde; 2002.

546.  Beringer P et al., eds. Remington: the science and practice of pharmacy. 21st. ed. Philadelphia: Lippincott Williams & Wilkins; 2006:1074.

 

SOBRE OS DIREITOS AUTORAIS DO DOCUMENTO

Consta no documento:

“Todos os direitos reservados. É permitida a reprodução parcial ou total desta obra, desde que citada a fonte e que não seja para venda ou qualquer fim comercial.”

O objetivo do site MedicinaNet e seus editores é divulgar este importante documento. Esta reprodução permanecerá aberta para não assinantes indefinidamente.

Voltar Topo